"Great innovations and new medicines are emerging in the animal health space, especially in terms of biologics and monoclonal antibodies, and we saw great opportunities in this developing area."
"We now offer an open platform for life sciences companies to have conversations around priorities in their field and discuss challenges in the supply chain."
"We progressed on the development of our New Innovative Products (NIP), which are complex generics developed using in-house proprietary technology platforms."
"We are beginning to see California move forward as not two or three individual clusters, but rather as a powerhouse of integrated clusters, and this will continue to be our focus in the future."
"In 2023, Massachusetts made up just shy of 15% of the national drug development pipeline and approximately 7% of the global drug development pipeline."
USA Mining 2025-26 pre-release is a snapshot capturing insights from over 70 executives and decision-makers across the value chain and from coast to coast, sharing not only how the industry is changing, but also where it is heading next.